Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Nutritional Neuroscience was a research-driven biotechnology company focused on developing nutritional interventions for neurological disorders, most notably Alzheimer's disease. Founded by Dr. Richard Wurtman of MIT, the company specialized in the Wurtman Consortium, a patented combination of nutrient precursors—uridine, choline, and omega-3 fatty acids—that work synergistically to enhance synaptic membrane formation. This scientific platform led to the development of Fortasyn Connect, the active component in the medical food Souvenaid, which is marketed globally by Nutricia (Danone). The company's work is foundational in the field of medical foods, demonstrating how specific metabolic precursors can influence neurodegenerative processes. Its research bridged the gap between traditional nutrition and neuropharmacology, providing a new therapeutic avenue for cognitive decline.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Nutritional Neuroscience.